- Home
- WAL vs LEGN Comparison
WAL vs LEGN Comparison
Compare WAL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WAL | LEGN |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | 3524 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WAL | LEGN |
|---|---|---|
| Price | $68.33 | $18.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $98.40 | $63.08 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.16 | $46.27 |
| Revenue Next Year | $8.63 | $28.77 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $16.24 |
| 52 Week High | $97.23 | $45.30 |
Technical Indicators
Market Signals| Indicator | WAL | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 46.94 |
| Support Level | N/A | $17.46 |
| Resistance Level | $79.68 | $21.58 |
| Average True Range (ATR) | 3.27 | 0.75 |
| MACD | -1.38 | 0.09 |
| Stochastic Oscillator | 3.96 | 36.86 |
Price Performance
Historical ComparisonAbout WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.